Treatment of Type 1 Diabetes with anti-OX40L Bispecific with anti-TNF Activity In a single Nanobody® molecule

Trial Identifier: ACT18368
Sponsor: Sanofi
Start Date: February 2025
Primary Completion Date: August 2027
Study Completion Date: September 2028
Condition: Diabetes: Type 1

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1119
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1178
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1419
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1180
ARGENTINA, Salta SALTA, Salta, ARGENTINA, 4400
AUSTRALIA, New South Wales SAINT LEONARDS, New South Wales, AUSTRALIA, 2065
AUSTRALIA, Queensland BRISBANE, Queensland, AUSTRALIA, 4029
AUSTRALIA, Victoria PARKVILLE, Victoria, AUSTRALIA, 3050
BRAZIL, Paraná CURITIBA, Paraná, BRAZIL, 80810-040
BRAZIL, São Paulo SÃO PAULO, São Paulo, BRAZIL, 01228-200
CANADA, British Columbia SURREY, British Columbia, CANADA, V3T 2V6
CANADA, British Columbia VANCOUVER, British Columbia, CANADA, V5Y 3W2
CHILE, Biobío Concepción, Biobío, CHILE, 4070566
CHILE, Reg Metropolitana de Santiago PROVIDENCIA, Reg Metropolitana de Santiago, CHILE, 7500000
CHILE, Reg Metropolitana de Santiago SANTIAGO, Reg Metropolitana de Santiago, CHILE, 7500505
ISRAEL JERUSALEM, ISRAEL, 9112001
ISRAEL KEFAR SAVA, ISRAEL, 4428164
ISRAEL RAMAT GAN, ISRAEL, 5262100
SAUDI ARABIA RIYADH, SAUDI ARABIA, 12713
UNITED STATES, Georgia ATLANTA, Georgia, UNITED STATES, 30318
UNITED STATES, Georgia COLUMBUS, Georgia, UNITED STATES, 31904
UNITED STATES, Michigan FARMINGTON HILLS, Michigan, UNITED STATES, 48334
UNITED STATES, Texas MCKINNEY, Texas, UNITED STATES, 75069
UNITED STATES, Utah OGDEN, Utah, UNITED STATES, 84405